BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
ARZERRA (ofatumumab) by Novartis is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2009.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARZERRA (ofatumumab) is a CD20-directed monoclonal antibody approved in 2009 for B-cell malignancies and autoimmune conditions. It works by binding to CD20 antigen on B cells, triggering cytolytic destruction of B-cell populations. The drug is administered via injection and represents a mature immunotherapy in a crowded CD20 competitor space.
LOE Approaching
ARZERRA faces significant lifecycle headwinds with LOE approaching and moderate competitive pressure (30/100); expect smaller brand teams and emphasis on managed decline strategies.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
Started Jul 2026
5,000 enrolled
Multiple Sclerosis
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
Started Apr 2026
7,466 enrolled
Multiple Sclerosis
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
Started Jan 2026
261 enrolled
Multiple Sclerosis
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Started Mar 2025
196 enrolled
Relapsing Multiple Sclerosis (RMS)
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Started Dec 2024
160 enrolled
Relapsing Multiple Sclerosis (RMS)
Worked on ARZERRA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.